Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy

Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy

Source: 
CP Wire
snippet: 
  • Plans to initiate trial in second half of 2018
  • Edasalonexent significantly slowed progression in Ph II trial
  • Edasalonexent is being developed as monotherapy or for use in combination